News

CHMP Recommends Approval of Givosiran for AHP in Europe

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended approval of Alnylam Pharmaceuticals’ givosiran for treating acute hepatic porphyria (AHP) in adults and adolescents 12 and older. If approved by the European Commission, givosiran will…

Non-Gastrointestinal Symptoms in Crohn’s Patients Could Signal Acute Intermittent Porphyria, Case Report Suggests

Abnormal non-gastrointestinal symptoms in patients with Crohn’s disease may indicate the presence of acute intermittent porphyria, a case report of a 23-year-old patient shows. The study, “Acute Intermittent Porphyria – an Unexpected Association in a Patient with Newly Diagnosed Crohn’s Disease,” was published in the Journal of…

Porphyria Diagnosed After PRES Suspected in Teenager

In an unusual case, a 16-year-old girl in India was diagnosed with acute intermittent porphyria (AIP) after radiological findings were suggestive of posterior reversible encephalopathy syndrome (PRES). The combination of abdominal pain with altered neurological and psychiatric status should alert clinicians to the possibility of porphyria, they said. The case…

Gene Therapy Takes Center Stage at 2019 NORD Summit

With so much recent publicity surrounding gene therapy, it’s no surprise that the topic was a major focus of the recent 2019 NORD Rare Diseases & Orphan Products Breakthrough Summit. From diagnosis and clinical trial design to manufacturing, pricing strategies, and ethical concerns, gene therapy — both its high…